BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

DuPont (DD) Leader Overviews 2012 Seed Research Pipeline with Investors


3/8/2012 9:07:06 AM

NEW YORK, March 7, 2012 /PRNewswire/ -- Innovative technology, local product advancements and a strong 2012 research pipeline have positioned DuPont's seed business, Pioneer Hi-Bred, for continued growth, Pioneer President Paul E. Schickler told attendees at the Goldman Sachs Agricultural Biotech Forum today.

"Global trends like an expanding middle class and rapid urbanization in developing economies are driving the demand for food and require constant innovation, global science and local solutions to feeding a growing population," said Schickler. "Pioneer is dedicated to meeting these challenges and building upon our double-digit sales growth in 2011 with the Right Product Right Acre strategy."

Schickler presented the 2012 seed research pipeline that features five product advancements and three program additions as a result of last year's R&D efforts. With many advancing programs close to commercialization, Pioneer also received 39 regulatory approvals in 2011 and submitted another 34 documents pending approval.

This year's pipeline advancements underscore Pioneer's success with the Optimum® AcreMax® family with a wave of insect protection products launching commercially in 2012. Together Optimum® AcreMax® 1 and Optimum® AcreMax® XTRA are anticipated to achieve 65 percent penetration of the company's above and below ground insect protection offering in North America.

"Our ability to innovate stems from our close relationships with growers as we look for new products and new ways to serve our customers," Schickler said.

Schickler used the Brazil soybean product evolution as an example of Pioneer's multi-pronged approach to product development. Pioneer® brand Y series soybeans on the market today have been developed specifically for that country. Using tools like the Accelerated Yield Technology (AYT) system and continual work with native traits, researchers are developing new varieties yearly with tolerance to local disease pressures. These products are backed by new technologies in the pipeline such as DuPont Dermacor® seed treatment that is expected to provide broad spectrum insect protection starting in 2014. Combined with local services and agronomic knowledge, this provides growers with a comprehensive product package.

To view a full copy of today's presentation, visit the "Events & Presentations" page on the DuPont Investor Center.

DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com.

Forward-Looking Statements: This news release contains forward-looking statements based on management's current expectations, estimates and projections. The company does not undertake to update any forward-looking statements as a result of future developments or new information. All statements that address expectations or projections about the future, including statements about the company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects," "anticipates," "plans," "intends," "projects," "indicates," and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in DuPont's filings with the Securities and Exchange Commission, particularly its latest annual report on Form 10-K, as well as others, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions of countries in which the company does business; competitive pressures; successful integration of structural changes, including acquisitions, divestitures and alliances; research and development of new products, including regulatory approval and market acceptance, and seasonality of sales of agricultural products.

The DuPont Oval Logo, DuPont, The miracles of science, Pioneer®, Optimum®, Dermacor®, AcreMax® and AYT are registered trademarks or trademarks of DuPont or its affiliates.

SOURCE DuPont



Read at BioSpace.com

DuPont
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES